Search the Newsreel

Immunocore to Detail Its Business and Portfolio on Aug. 6

Immunocore (NASDAQ: IMCR) will release its second-quarter 2026 financial results on Thursday, August 6, 2026, for the period ending June 30, 2026. The company will host a live teleconference and webcast at 8:00 a.m. EDT to discuss the results and provide updates on its …

Immutep's IMP761 Shows Immune Activity in First-in-Human Trial

Immutep (NASDAQ: IMMP) released its Q4 FY26 activities report, detailing new clinical, intellectual property, and financial developments. Key highlights include positive pooled analysis from efti trials showing a 7.7-month median overall survival benefit for biological responders and promising first-in-human data for IMP761, which met …

Immunocore to report second quarter 2026 financial results and host call on August 6, 2026

Immunocore Holdings plc (Nasdaq: IMCR) announced it will report its financial results for the second quarter ended June 30, 2026, on Thursday, August 6, 2026. Following the announcement, the company will host a live teleconference and webcast at 8:00 AM ET to discuss these …

Immersion Corp (IMMR) Institutional Confidence

This article analyzes the institutional confidence in Immersion Corp (IMMR), showing its current score of 5.00 and ranking 220th in the Software & IT Services industry. Institutional shareholding proportion increased by 0.29% quarter-over-quarter to 53.79%, with ETHSX being the largest institutional shareholder. The report …

Immunocore Holdings PLC (IMCR) Valuation: PE, PB & Fair Value Analysis

The article provides a valuation analysis for Immunocore Holdings PLC (IMCR), noting its current valuation score of 9.63, ranking 13th in the Pharmaceuticals industry. The company's P/E ratio is -60.75, which is significantly below its recent high and above its recent low. Key valuation …

Shimmick Corp (SHIM) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a risk assessment for Shimmick Corp (SHIM), highlighting its current risk score of 2.59, which ranks 35 out of 41 in the Construction & Engineering industry. The company's beta value of 0.00 suggests it underperforms during market upturns but sees smaller …

ImmunityBio stock jumps on UAE drug approval for ANKTIVA

ImmunityBio's shares rose 7.5% after the United Arab Emirates approved its drug ANKTIVA for two indications: BCG-unresponsive non-muscle invasive bladder cancer and metastatic non-small cell lung cancer. This approval expands ANKTIVA's global regulatory footprint to 34 countries and is the first worldwide approval for …

Immunovant (IMVT) Projected to Announce Earnings on Thursday

IMRX|Immuneering Corp|Price:4.165|Chg%:+0.035

Immunocore (IMCR) Projected to Release Quarterly Earnings on Thursday

Shimmick Corp (SHIM) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Shimmick Corp (SHIM), detailing its current price momentum score, support and resistance levels for range-bound trading, and readings from various technical indicators and moving averages. While the overall technical indicators show a neutral signal, the moving averages …

BMNR|BitMine Immersion Technologies Ord Shs|Price:16.585|Chg%:-0.985

BitMine Immersion Technologies (BMNR) saw its stock price drop by 5.61% to $16.585. Despite strong fundamentals and significant growth potential, the stock is currently in a sideways trading pattern, suggesting it's suitable for range-bound swing trading. Analysts rate BMNR as a "Buy" with a …

Zimmer Biomet (ZBH) Is Up 7.7% After Q1 Beat And Confident Outlook Commentary - What's Changed

Zimmer Biomet (ZBH) saw its stock rise by 7.7% following a strong first-quarter performance, with revenues up 9.3% year-on-year and earnings surpassing analyst expectations. The company's confident outlook, driven by its robotics and efficiency investments, reinforces its investment narrative despite potential risks from pricing …

Shimmick Corp (SHIM) Financial Health: Profitability & Balance Sheet Analysis

Shimmick Corp (SHIM) has a weak financial status and average operating efficiency, ranking 36 out of 41 in the Construction & Engineering industry with a financial score of 6.45. Its latest quarterly revenue decreased by 27.91% year-over-year, and net profit declined by 53.41% over …

Simmons First National Corporation Class A Revenue Breakdown – FWB:SN9

Simmons First National Corporation Class A (FWB:SN9) generated 770.79 million EUR in revenue last year, with its Community and Commercial Banking segment being the top performer contributing 52.45 million EUR. The majority of the company's revenue, 87.89 million EUR, originated from the United States. …

Lyell Immunopharma Inc (LYEL) Risk Assessment: Volatility, Financial Risk & Investment Risk

Lyell Immunopharma Inc (LYEL) has a current risk assessment score of 2.20, ranking 230 out of 384 in the Biotechnology & Medical Research industry. The company's beta value of -0.09 suggests it tends to underperform during market uptrends but experiences smaller declines during downtrends. …

Dow, S&P 500, Nasdaq Futures Rise As Investors Shrug Off Fed Hold, Big Tech Earnings: IBRX, MSFT, SOFI, META In Focus

Immatics Number of Employees 2026 | Employee Count & Headcount Data

Immatics NV (NASDAQ: IMTX) had 426 employees worldwide as of March 2026, representing a 54.3% growth from 2023. The company, headquartered in Germany, is actively hiring with 45 job postings in 2026 and its workforce is primarily concentrated in Germany and the United States. …

Immatics (IMTX) general counsel Pepin Nelson reports insider status

Immatics N.V. (IMTX) general counsel and corporate secretary Pepin James Nelson has filed an initial statement of beneficial ownership (Form 3), establishing his insider status. The filing indicates no reported equity or derivative transactions, classifying him as an officer-reporting person. The document also notes …

ImmunityBio Receives United Arab Emirates (UAE) Marketing Authorization for ANKTIVA® Across BCG-Unresponsive Non-Muscle Invasive Bladder Cancer for CIS and Papillary Disease and Metastatic Non-Small Cell Lung Cancer

ImmunityBio announced that the Emirates Drug Establishment (EDE) of the United Arab Emirates (UAE) has granted Marketing Authorization for ANKTIVA across two indications: BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) and metastatic non-small cell lung cancer (NSCLC). This marks the fifth regulatory approval for ANKTIVA …

ZIMMER BIOMET HOLDINGS, INC : UBS ASSUMES COVERAGE WITH BUY VS SELL RATING; PRICE TARGET $115 VS $89

UBS has initiated coverage on Zimmer Biomet Holdings, Inc. with a "Buy" rating, significantly increasing its price target to $115 from a previous "Sell" rating and target of $89. This upgrade from UBS indicates a positive outlook for the company's stock.

Estrella Immunopharma Activates Baylor Scott & White Research Institute as Second Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma

Estrella Immunopharma announced the activation of Baylor Scott & White Research Institute as the second clinical site for its Phase I/II STARLIGHT-1 trial. This trial evaluates EB103, a CD19-Redirected ARTEMIS® T-cell therapy, for patients with relapsed or refractory B-cell non-Hodgkin’s lymphoma (NHL). The expansion …

Simmons First National Corporation $SFNC Stock Position Reduced by Rhino Investment Partners Inc

Rhino Investment Partners Inc. significantly reduced its stake in Simmons First National Corporation (SFNC) by 46.9% in Q1 2026, selling over 642,000 shares but still retaining 726,883 shares valued at $14.1 million. Despite this, other institutional investors like Vanguard Group and State Street Corp …

ImmuCell Corporation Revenue Breakdown – NASDAQ:ICCC

Zimmer Biomet Set to Report Q2 Earnings: What's in the Cards?

Zimmer Biomet (ZBH) is expected to report its second-quarter 2026 earnings on August 5th, with revenue estimates of $2.13 billion and EPS of $2.01. The company's performance is anticipated to be driven by strong demand in its Knees, Hips, S.E.T (Sports Medicine, Upper Extremities, …

Estrella Immunopharma, Inc. Revenue Breakdown – NASDAQ:ESLAW

This article provides a basic overview of Estrella Immunopharma, Inc. (NASDAQ: ESLAW) financial information available on TradingView, focusing on its revenue breakdown. It indicates that further details regarding segment and regional performance by source and country can be accessed through the platform. The content …

H.C. Wainwright reiterates Altimmune stock rating on trial results

H.C. Wainwright has reiterated a Buy rating and a $20.00 price target for Altimmune (NASDAQ:ALT) following positive Phase 2 trial results for its drug candidate, pemvidutide, in treating alcohol use disorder. The drug met its primary endpoint by significantly reducing heavy drinking days and …

Estrella activates second site for EB103 lymphoma trial By Investing.com

Estrella Immunopharma, Inc. has activated a second clinical site, Baylor Scott & White Research Institute, for its STARLIGHT-1 Phase I/II trial evaluating EB103 for relapsed or refractory B-cell non-Hodgkin’s lymphoma. This expansion aims to broaden the trial's reach and gather more data to determine …

Estrella Immunopharma Inc (ESLA) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis for Estrella Immunopharma Inc (ESLA), focusing on its PE, PB, and fair value. It includes current stock performance metrics and links to further financial data and company overviews.

Zimmer Biomet Holdings Inc (ZBH) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Zimmer Biomet Holdings Inc (ZBH), detailing its current price momentum score, support and resistance levels, and insights from various technical indicators and moving averages. The analysis suggests the stock is currently suitable for range-bound swing trading, with …

Enterprise value to revenue forward of Lyell Immunopharma, Inc. – NASDAQ:LYEL

Immunocore Holdings PLC (IMCR) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Immunocore Holdings PLC (IMCR), focusing on its support and resistance levels, various technical indicators, and moving averages. As of July 28, 2026, IMCR's price momentum score is 3.98, and the stock is trading between a resistance of …

LYEL|Lyell Immunopharma Inc|Price:13.000|Chg%:+0.040

TradingKey provides a comprehensive stock analysis for Lyell Immunopharma Inc (LYEL), highlighting its relatively healthy fundamentals, significant growth potential, and fair valuation within the Biotechnology & Medical Research industry. The company, a late-stage clinical entity developing CAR T-cell therapies, has high institutional ownership and …

Immunic Inc (IMUX) Financial Health: Profitability & Balance Sheet Analysis

This article provides a financial health analysis of Immunic Inc (IMUX) based on TradingKey's assessment. It highlights the company's current financial score of 7.02, ranking 166 out of 385 in the Biotechnology & Medical Research industry, indicating a robust financial status but low operating …

Price to book forward of Lyell Immunopharma, Inc. – NASDAQ:LYEL

This article provides the "Price to book forward" value for Lyell Immunopharma, Inc. (NASDAQ: LYEL). It is a brief financial data point from TradingView, part of a larger financial overview for the company. The content primarily focuses on the specific metric within the platform's …

Altimmune Inc RECLAIM Phase 2 Trial in AUD Topline Results Conference Call Transcript

This article provides the transcript for Altimmune Inc.'s RECLAIM Phase 2 Trial in AUD Topline Results Conference Call held on July 28, 2026. The call began with an introduction by Louis Sine, Vice President of Investor Relations, and detailed how participants could ask questions. …